Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Gonzalez D, Cunningham D, Hulkki Wilson S, Peckitt C, Giralt J, Glimelius B, Roselló Keränen S, Wotherspoon A, Brown G, Tait D, Oates J, Chau I.

Eur J Cancer. 2014 May;50(8):1430-6. doi: 10.1016/j.ejca.2014.02.002. Epub 2014 Feb 28.

PMID:
24582914
2.

Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).

Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, Gonzalez de Castro D, Chua YJ, Wong R, Barbachano Y, Oates J, Chau I.

J Clin Oncol. 2012 May 10;30(14):1620-7. doi: 10.1200/JCO.2011.39.6036. Epub 2012 Apr 2.

PMID:
22473163
3.

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab.

Sclafani F, Roy A, Cunningham D, Wotherspoon A, Peckitt C, Gonzalez de Castro D, Tabernero J, Glimelius B, Cervantes A, Eltahir Z, Oates J, Chau I.

Ann Oncol. 2013 Dec;24(12):3123-8. doi: 10.1093/annonc/mdt408. Epub 2013 Oct 20.

PMID:
24146218
4.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S.

Lancet Oncol. 2010 Aug;11(8):753-62. doi: 10.1016/S1470-2045(10)70130-3. Epub 2010 Jul 8.

PMID:
20619739
5.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridgewater J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP; MRC COIN Trial Investigators.

Lancet. 2011 Jun 18;377(9783):2103-14. doi: 10.1016/S0140-6736(11)60613-2. Epub 2011 Jun 5.

6.

Preoperative chemoradiation therapy with capecitabine/oxaliplatin and cetuximab in rectal cancer: long-term results of a prospective phase 1/2 study.

Fokas E, Conradi L, Weiss C, Sprenger T, Middel P, Rau T, Dellas K, Kitz J, Rödel F, Sauer R, Rüschoff J, Beissbarth T, Arnold D, Ghadimi BM, Rödel C, Liersch T.

Int J Radiat Oncol Biol Phys. 2013 Dec 1;87(5):992-9. doi: 10.1016/j.ijrobp.2013.09.011. Epub 2013 Oct 24.

PMID:
24210078
7.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.

Sclafani F, Chau I, Cunningham D, Peckitt C, Lampis A, Hahne JC, Braconi C, Tabernero J, Glimelius B, Cervantes A, Begum R, Gonzalez De Castro D, Hulkki Wilson S, Eltahir Z, Wotherspoon A, Tait D, Brown G, Oates J, Valeri N.

Ann Oncol. 2015 Sep;26(9):1936-41. doi: 10.1093/annonc/mdv285. Epub 2015 Jul 10.

8.

KRAS mutation status and clinical outcome of preoperative chemoradiation with cetuximab in locally advanced rectal cancer: a pooled analysis of 2 phase II trials.

Kim SY, Shim EK, Yeo HY, Baek JY, Hong YS, Kim DY, Kim TW, Kim JH, Im SA, Jung KH, Chang HJ.

Int J Radiat Oncol Biol Phys. 2013 Jan 1;85(1):201-7. doi: 10.1016/j.ijrobp.2012.03.048. Epub 2012 Jun 5.

PMID:
22672749
9.

FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer.

Bokemeyer C, Köhne CH, Ciardiello F, Lenz HJ, Heinemann V, Klinkhardt U, Beier F, Duecker K, van Krieken JH, Tejpar S.

Eur J Cancer. 2015 Jul;51(10):1243-52. doi: 10.1016/j.ejca.2015.04.007. Epub 2015 Apr 30.

PMID:
25937522
10.

Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.

Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.

J Clin Oncol. 2011 Mar 10;29(8):1050-8. doi: 10.1200/JCO.2010.31.1936. Epub 2011 Feb 7.

PMID:
21300933
11.

KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.

Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G, Kienle P, Post S, Wenz F, Hochhaus A, Hofheinz RD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1032-8. doi: 10.1016/j.ijrobp.2010.06.043. Epub 2010 Oct 13.

PMID:
20947270
12.

A prospective pilot study of target-guided personalized chemotherapy with intensity-modulated radiotherapy in patients with early rectal cancer.

Cubillo A, Hernando-Requejo O, García-García E, Rodriguez-Pascual J, De Vicente E, Morelli P, Rubio C, López-Ríos F, Muro A, López U, Prados S, Quijano Y, Hidalgo M.

Am J Clin Oncol. 2014 Apr;37(2):117-21. doi: 10.1097/COC.0b013e31826e0703.

PMID:
23211222
13.

Effect of neoadjuvant cetuximab, capecitabine, and radiotherapy for locally advanced rectal cancer: results of a phase II study.

Sun PL, Li B, Ye QF.

Int J Colorectal Dis. 2012 Oct;27(10):1325-32. Epub 2012 Mar 20.

PMID:
22430888
14.

FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.

Kaczirek K, Ciuleanu TE, Vrbanec D, Marton E, Messinger D, Liegl-Atzwanger B, Wrba F, Knittelfelder R, Lindner E, Zielinski CC, Streubel B, Brodowicz T.

Clin Colorectal Cancer. 2015 Jun;14(2):91-8. doi: 10.1016/j.clcc.2014.12.003. Epub 2014 Dec 24.

PMID:
25666295
15.

Adjuvant FOLFOX +/- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients.

Taieb J, Balogoun R, Le Malicot K, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Emile JF, Mulot C, Fratté S, Levaché CB, Saban-Roche L, Thaler J, Petersen LN, Bridgewater J, Perkins G, Lepage C, Van Cutsem E, Zaanan A, Laurent-Puig P; PETACC8 Investigators.

Ann Oncol. 2017 Apr 1;28(4):824-830. doi: 10.1093/annonc/mdw687.

PMID:
28031175
16.

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer.

Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ.

N Engl J Med. 2009 Feb 5;360(6):563-72. doi: 10.1056/NEJMoa0808268. Erratum in: N Engl J Med. 2010 Dec 23;363(26):2573.

17.

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

Di Bartolomeo M, Pietrantonio F, Perrone F, Dotti KF, Lampis A, Bertan C, Beretta E, Rimassa L, Carbone C, Biondani P, Passalacqua R, Pilotti S, Bajetta E; Italian Trials in Medical Oncology Group.

Target Oncol. 2014 Jun;9(2):155-62. doi: 10.1007/s11523-013-0283-8. Epub 2013 Jul 3.

PMID:
23821376
18.

Combined KRAS and TP53 mutation status is not predictive in CAPOX-treated metastatic colorectal cancer.

De Bruijn MT, Raats DA, Tol J, Hinrichs J, Teerenstra S, Punt CJ, Rinkes IH, Kranenburg O.

Anticancer Res. 2011 Apr;31(4):1379-85.

PMID:
21508389
19.

KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.

Kullmann F, Hartmann A, Stöhr R, Messmann H, Dollinger MM, Trojan J, Fuchs M, Hollerbach S, Harder J, Troppmann M, Kutscheidt A, Endlicher E.

Oncology. 2011;81(1):3-8. doi: 10.1159/000330194. Epub 2011 Sep 2.

PMID:
21894049
20.

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

Taieb J, Tabernero J, Mini E, Subtil F, Folprecht G, Van Laethem JL, Thaler J, Bridgewater J, Petersen LN, Blons H, Collette L, Van Cutsem E, Rougier P, Salazar R, Bedenne L, Emile JF, Laurent-Puig P, Lepage C; PETACC-8 Study Investigators.

Lancet Oncol. 2014 Jul;15(8):862-73. doi: 10.1016/S1470-2045(14)70227-X. Epub 2014 Jun 11.

Supplemental Content

Support Center